Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells

[1]  Junhong Han,et al.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. , 2019, Signal transduction and targeted therapy.

[2]  Bing-he Xu,et al.  Targeted therapeutic options and future perspectives for HER2-positive breast cancer , 2019, Signal Transduction and Targeted Therapy.

[3]  R. Bernards,et al.  PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[5]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[6]  J. Ajani,et al.  A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. , 2019, European journal of cancer.

[7]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[8]  J. Baselga,et al.  Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer , 2018, Cancer Chemotherapy and Pharmacology.

[9]  Y. Kakeji,et al.  3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture. , 2018, Anticancer research.

[10]  Carsten Denkert,et al.  Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). , 2017, European journal of cancer.

[11]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[12]  F. Janku.  Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. , 2017, Cancer treatment reviews.

[13]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. , 2017, The Lancet. Oncology.

[14]  M. Dowsett,et al.  Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer , 2017, Breast Cancer Research.

[15]  C. Isaacs,et al.  Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Bernards,et al.  PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Jungsil Ro,et al.  Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[18]  D. A. Foster,et al.  The Enigma of Rapamycin Dosage , 2016, Molecular Cancer Therapeutics.

[19]  Q. Peng,et al.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review) , 2015, International journal of oncology.

[20]  Ken Chen,et al.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. , 2015, Cancer research.

[21]  Qingyuan Zhang,et al.  Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. , 2015, The Lancet. Oncology.

[22]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[24]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Carsten Denkert,et al.  PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Bing-he Xu,et al.  Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone , 2014, Breast Cancer Research.

[27]  Bing-he Xu,et al.  Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone , 2014, Breast Cancer Research.

[28]  C. Isaacs,et al.  Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[29]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[30]  Razelle Kurzrock,et al.  Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. , 2014, Cell reports.

[31]  C. Arteaga,et al.  Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells , 2014, Breast Cancer Research.

[32]  S. Loi,et al.  Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. , 2013, Cancer treatment reviews.

[33]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Sotiriou,et al.  Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer , 2013, Journal of the National Cancer Institute.

[35]  Tyler T. Risom,et al.  Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models , 2013, Clinical Cancer Research.

[36]  B. Brandhuber,et al.  An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt , 2012, Science Signaling.

[37]  J. Baselga,et al.  Dual Mtorc1/2 and Her2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-her2 Therapy Statement of Translational Relevance , 2022 .

[38]  V. Rodrik-Outmezguine,et al.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1 , 2011, Cell cycle.

[39]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[40]  S. Chandarlapaty,et al.  PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer , 2011, Oncogene.

[41]  H. Gómez,et al.  The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer , 2010, Cancer and Metastasis Reviews.

[42]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[43]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[44]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[45]  Violeta Serra,et al.  Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. , 2008, Cancer research.

[46]  G. Hortobagyi,et al.  Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells , 2008, Molecular Cancer Therapeutics.

[47]  R. Nahta,et al.  Her2 cross talk and therapeutic resistance in breast cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[48]  G. Mills,et al.  Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency , 2007, Clinical Cancer Research.

[49]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[50]  S. Hilsenbeck,et al.  Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. , 2006, Cancer research.

[51]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[52]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[53]  N. Terada.  [Enigma of rapamycin]. , 1995, Seikagaku. The Journal of Japanese Biochemical Society.

[54]  A. Gingras,et al.  Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function , 1994, Nature.